Albanien
Bosnien-Herzegowina
Bulgarien
Kroatien
Zypern
Montenegro
Tschechien
Dänemark
Estland
Spanien
Kosovo
Litauen
Lettland
Luxemburg
Mazedonien
Deutschland
Polen
Portugal
Rumänien
Serbien
Slowakei
Slowenien
Schweiz
Schweden
Türkei
Ukraine
Ungarn
Großbritannien
Italien
UAE
Hong Kong
Kuwait
Libanon
Südafrika
Unsere
Transplantationen
Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:
Lp.
Quelle
Quellentyp
Diagnose
Medizinbereich
Anwendungsjahr
Therapie
Land
Alter des Empfängers
Alles
Alles
Alles
Alles
Alles
Alles
Alles
Alles
1
Cord Tissue
Allogeneic - Related
Chronic renal disease
Endocrinology
2025
Experimental Therapy
Romania
50
2
Cord Tissue
Allogeneic - Related
Autism
Neurology
2025
Experimental Therapy
Romania
6
3
Cord Tissue
Autologous
Autism
Neurology
2025
Experimental Therapy
Romania
6
4
Cord Tissue
Allogeneic - Unrelated
Degenerative and traumatic cartilage damage
Orthopedy
2025
Experimental Therapy
Poland
57
5
Cord Tissue
Allogeneic - Unrelated
Cerebral Palsy
Neurology
2025
Experimental Therapy
Poland
3
6
Cord Tissue
Allogeneic - Unrelated
Cerebral Palsy
Neurology
2025
Experimental Therapy
Poland
3
7
Cord Tissue
Allogeneic - Unrelated
Cerebral Palsy
Neurology
2025
Experimental Therapy
Poland
2
8
Cord Tissue
Allogeneic - Unrelated
Autism
Neurology
2025
Experimental Therapy
Poland
5
9
Cord Tissue
Allogeneic - Unrelated
Cerebral Palsy
Neurology
2025
Experimental Therapy
Poland
11
10
Cord Blood
Allogeneic - Related
Thalassemia Major
Hematology
2025
Standard Therapy
Turkey
5
11
Cord Blood
Autologous
Aplastic Anemia
Hematology
2025
Standard Therapy
Poland
2
12
Bone Marrow Family
Allogeneic
Myelofibrosis
Hematology
2025
Standard Therapy
Poland
71
13
Bone Marrow Family
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
United Kingdom
72
14
Bone Marrow Family
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
France
47
15
Bone Marrow Family
Allogeneic
Myelodysplastic Syndrome
Hematology
2025
Standard Therapy
Ukraine
43
16
Bone Marrow Family
Allogeneic
Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
Italy
49
17
Bone Marrow Family
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
France
51
18
Bone Marrow Family
Allogeneic
Philadelphia - positive Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
Germany
61
19
Bone Marrow Family
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
France
58
20
Bone Marrow Family
Allogeneic
Myelofibrosis
Hematology
2025
Standard Therapy
NETHERLANDS
63
21
Bone Marrow Family
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Poland
65
22
Bone Marrow Family
Allogeneic
Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
France
63
23
Bone Marrow
Allogeneic
Aplastic Anemia
Hematology
2025
Standard Therapy
Spain
15
24
Bone Marrow
Allogeneic
Severe Aplastic Anemia
Hematology
2025
Standard Therapy
Norway
55
25
Bone Marrow
Allogeneic
Inherited Immune System Disorder
Hematology
2025
Standard Therapy
France
3
26
Bone Marrow
Allogeneic
Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
USA
7
27
Bone Marrow
Allogeneic
Severe Aplastic Anemia
Hematology
2025
Standard Therapy
Ukraine
36
28
Bone Marrow
Allogeneic
Inherited Immune System Disorder
Hematology
2025
Standard Therapy
France
10
29
Bone Marrow
Allogeneic
Myelodysplastic Syndrome
Hematology
2025
Standard Therapy
USA
76
30
Bone Marrow
Allogeneic
Severe Aplastic Anemia
Hematology
2025
Standard Therapy
Poland
39
31
Bone Marrow
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
South Africa
6
32
Bone Marrow
Allogeneic
Wiskott-Aldrich syndrome
Hematology
2025
Standard Therapy
Turkey
6
33
Bone Marrow
Allogeneic
Combined immnunodeficiency
Hematology
2025
Standard Therapy
Ukraine
3
34
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Germany
58
35
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
USA
34
36
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Italy
61
37
Apheresis
Allogeneic
Myelodysplastic Syndrome/Myeloproliferative neoplasm
Hematology
2025
Standard Therapy
NETHERLANDS
62
38
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Austria
68
39
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Germany
70
40
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Germany
66
41
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
USA
77
42
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Ukraine
12
43
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Germany
58
44
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
USA
67
45
Apheresis
Allogeneic
Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
Poland
4
46
Apheresis
Allogeneic
Myelofibrosis Myeloid Metaplasia
Hematology
2025
Standard Therapy
USA
73
47
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Germany
56
48
Apheresis
Allogeneic
Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
Italy
50
49
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Poland
39
50
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Lithuania
43
51
Apheresis
Allogeneic
Chronic Myelomonocytic Leukemia
Hematology
2025
Standard Therapy
Poland
66
52
Apheresis
Allogeneic
Multiple Myeloma
Hematology
2025
Standard Therapy
USA
61
53
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Austria
55
54
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Italy
69
55
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Denmark
67
56
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2025
Standard Therapy
United Kingdom
75
57
Apheresis
Allogeneic
T - cell Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
Poland
24
58
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2025
Standard Therapy
Belgium
68
59
Apheresis
Allogeneic
Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
Ukraine
42
60
Apheresis
Allogeneic
Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
USA
50
61
Apheresis
Allogeneic
Prolymphocytic Leukemia
Hematology
2025
Standard Therapy
USA
62
62
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2025
Standard Therapy
United Kingdom
62
63
Apheresis
Allogeneic
Chronic Myelomonocytic Leukemia
Hematology
2025
Standard Therapy
USA
69
64
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Germany
85
65
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
USA
54
66
Apheresis
Allogeneic
Non-Hodgkin Lymphoma
Hematology
2025
Standard Therapy
USA
39
67
Apheresis
Autologous
Multiple myeloma
Hematology
2025
Standard Therapy
Germany
45
68
Apheresis
Autologous
Acute myeloid leukemia
Hematology
2025
Standard Therapy
Germany
59
69
Apheresis
Allogeneic
Multiple myeloma
Hematology
2025
Standard Therapy
Germany
68
70
Apheresis
Allogeneic
Multiple myeloma
Hematology
2025
Standard Therapy
Germany
68
71
Apheresis
Autologous
Multiple myeloma
Hematology
2025
Standard Therapy
Germany
73
72
Apheresis
Autologous
Multiple myeloma
Hematology
2025
Standard Therapy
Germany
66
73
Apheresis
Autologous
Acute myeloid leukemia
Hematology
2025
Standard Therapy
Germany
69
74
Apheresis
Autologous
Hodgkin lymphoma
Hematology
2025
Standard Therapy
Germany
38
75
Apheresis
Allogeneic
Tcell acute leukemia
Hematology
2025
Standard Therapy
Romania
31
76
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Italy
37
77
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Sweden
69
78
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
USA
55
79
Apheresis
Allogeneic
Fanconi's Anemia
Hematology
2025
Standard Therapy
Russia
14
80
Apheresis
Allogeneic
Peripheral T-cell Lymphoma not otherwise specified
Hematology
2025
Standard Therapy
Germany
54
81
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
France
63
82
Apheresis
Allogeneic
Myeloid Sarcoma
Hematology
2025
Standard Therapy
Poland
48
83
Apheresis
Allogeneic
Other Myelofibrosis/Myelosclerosis
Hematology
2025
Standard Therapy
USA
72
84
Apheresis
Allogeneic
Severe Aplastic Anemia
Hematology
2025
Standard Therapy
Germany
11
85
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
USA
37
86
Apheresis
Allogeneic
Myelofibrosis
Hematology
2025
Standard Therapy
Australia
59
87
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
USA
35
88
Apheresis
Allogeneic
Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
Poland
51
89
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Germany
59
90
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2025
Standard Therapy
Poland
70
91
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2025
Standard Therapy
USA
70
92
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
USA
66
93
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Germany
63
94
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Germany
66
95
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2025
Standard Therapy
Italy
61
96
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
USA
71
97
Apheresis
Allogeneic
Chronic Lymphocytic Leukemia
Hematology
2025
Standard Therapy
Czechia
45
98
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
Brazil
61
99
Apheresis
Allogeneic
Acute Lymphoblastic Leukemia
Hematology
2025
Standard Therapy
Hungary
35
100
Apheresis
Allogeneic
Acute Myelogenous Leukemia
Hematology
2025
Standard Therapy
NETHERLANDS
48
Seitevon75
100 Reihen
Laden